Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
- 1 May 1995
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 345 (8961), 1321-1325
- https://doi.org/10.1016/s0140-6736(95)92534-1
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- THE IMPACT OF ACUTE REJECTION EPISODES ON LONG-TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENSTransplantation, 1993
- International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathologyKidney International, 1993
- Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single CenterAnnals of Surgery, 1993
- LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1993
- RS-61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant RejectionAnnals of Surgery, 1992
- A RANDOMIZED TRIAL OF CYCLOSPORINE AND PREDNISOLONE VERSUS CYCLOSPORINE, AZATHIOPRINE, AND PREDNISOLONE IN PRIMARY CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1992
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- RS-61443—A NEW, POTENT IMMUNOSUPPRESSIVE AGENTTransplantation, 1991